Allarity Therapeutics Files 8-K
Ticker: ALLR · Form: 8-K · Filed: Nov 19, 2024 · CIK: 1860657
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
ALLARITY THERAPEUTICS FILED AN 8-K. NO DETAILS YET.
AI Summary
Allarity Therapeutics, Inc. filed an 8-K on November 18, 2024, reporting other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.
Why It Matters
This filing indicates a regulatory update from Allarity Therapeutics, Inc., which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K without immediate financial implications or significant disclosures in the provided text.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- November 18, 2024 (date) — Date of earliest event reported
- 24 School Street, 2nd Floor, Boston, MA 02108 (address) — Principal executive offices
- 401-426-4664 (phone_number) — Registrant's telephone number
FAQ
What specific 'Other Events' are being reported by Allarity Therapeutics, Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events' being reported.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 18, 2024.
What is the principal executive office address for Allarity Therapeutics, Inc.?
The principal executive office address for Allarity Therapeutics, Inc. is 24 School Street, 2nd Floor, Boston, MA 02108.
What is the telephone number for Allarity Therapeutics, Inc.?
The telephone number for Allarity Therapeutics, Inc. is (401) 426-4664.
What is the SIC code for Allarity Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Allarity Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 462 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-11-19 08:00:31
Key Financial Figures
- $0.0001 — ch registered Common Stock , par value $0.0001 per share ALLR The Nasdaq Stock Mark
Filing Documents
- allr20241118_8k.htm (8-K) — 29KB
- ex_749318.htm (EX-99.1) — 19KB
- atlogosmall.jpg (GRAPHIC) — 6KB
- 0001437749-24-035686.txt ( ) — 198KB
- allr-20241118.xsd (EX-101.SCH) — 3KB
- allr-20241118_def.xml (EX-101.DEF) — 12KB
- allr-20241118_lab.xml (EX-101.LAB) — 16KB
- allr-20241118_pre.xml (EX-101.PRE) — 12KB
- allr20241118_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On November 18, 2024, Allarity Therapeutics, Inc. (the "Company") issued a press release providing a corporate update highlighting three significant developments: extended treatment duration for patients in its ongoing Phase 2 stenoparib trial, a strengthened cash position supporting initiation of a follow-up FDA registrational trial, and new revenue-generating activities from the Company's laboratory services. The Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated November 18, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: November 19, 2024 By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer